Opticyte
Seattle
About Opticyte
Opticyte, Inc, a medical device innovator developing proprietary advanced algorithms and tailored optical spectroscopy technology to measure and detect low oxygen levels in cells to prevent organ failure. Opticyte is developing the first Cell O2 Monitor for reducing organ failure. Founded in 2016, Opticyte, Inc, is a spinoff from the University of Washington. Headquartered in Seattle, WA, Opticyte employs engineering, regulatory, and communications teams with deep experience in bringing medical devices to market.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $5.7M
- Funding stage: Seed
- Last round: Non-Equity Assistance (Jun 2023)
- Website: opticyte.com
- Phone: [email protected]
Industries & Categories
Medical Device
Social Profiles
Canonical: https://fsome.com/organization/opticyte-50714 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.